Considering that PD-L1+ CSCs may contribute to NSCLC aggressiveness and resistance to conventional therapies, they may serve as a potential factor for prognostic evaluation of NSCLC and help in designing promising immune-based therapeutic strategies. Here, CD274 is linked to non-small cell lung carcinoma.